Supplemental material
Report
NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies
Corinna Laua Research Laboratory, Nordland Hospital Trust, Bodø, NorwayCorrespondence[email protected]
https://orcid.org/0000-0003-1750-8065View further author information
https://orcid.org/0000-0003-1750-8065View further author information, Martin Berner McAdamb Department of Immunology, Oslo University Hospital-Rikshospitalet, and Centre for Immune Regulation, Oslo, Norwayhttps://orcid.org/0000-0001-9385-6964View further author information
https://orcid.org/0000-0001-9385-6964View further author information, , , Jack Ansgar Bruund Department of Medical Biology, Proteomics Platform, University of Tromsø, Tromsø, Norwayhttps://orcid.org/0000-0003-0614-2790View further author information
https://orcid.org/0000-0003-0614-2790View further author information, , Hilde Furea Research Laboratory, Nordland Hospital Trust, Bodø, Norwayhttps://orcid.org/0000-0002-3634-0969View further author information
https://orcid.org/0000-0002-3634-0969View further author information, Terje Espevike Centre of Molecular Inflammation Research, and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norwayhttps://orcid.org/0000-0003-0354-5068View further author information
https://orcid.org/0000-0003-0354-5068View further author information, Anders Moenf Department of Biosciences, Proteomics core facility, University of Oslo, Oslo, Norwayhttps://orcid.org/0000-0002-6936-0747View further author information
https://orcid.org/0000-0002-6936-0747View further author information, Jan Terje Andersenb Department of Immunology, Oslo University Hospital-Rikshospitalet, and Centre for Immune Regulation, Oslo, Norway;g Department of Pharmacology, Institute of Clinical Medicine, Oslo University Hospital and University of Oslo, Oslo, Norwayhttps://orcid.org/0000-0003-1710-1628View further author information
https://orcid.org/0000-0003-1710-1628View further author information & Tom Eirik Mollnesa Research Laboratory, Nordland Hospital Trust, Bodø, Norway;e Centre of Molecular Inflammation Research, and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway;h Department of Immunology, Oslo University Hospital, University of Oslo, Oslo, Norway;i Faculty of Health Sciences and K. G. Jebsen TREC, University of Tromsø, Tromsø, Norwayhttps://orcid.org/0000-0002-5785-802XView further author information
https://orcid.org/0000-0002-5785-802XView further author information show allRelated Research Data
Double Blockade of CD14 and Complement C5 Abolishes the Cytokine Storm and Improves Morbidity and Survival in Polymicrobial Sepsis in Mice
Source:
The American Association of Immunologists
Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy
Source:
SpringerOpen
Combined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis
Source:
BioMed Central
Structure and function of immunoglobulins.
Source:
Elsevier BV
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life.
Source:
Frontiers Media SA
CD14 is a pattern recognition receptor.
Source:
Elsevier BV
Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.
Source:
Elsevier BV
CD14 is a coreceptor of Toll-like receptors 7 and 9
Source:
Rockefeller University Press
Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets.
Source:
Society for Leukocyte Biology
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Source:
Oxford University Press (OUP)
Bride and groom in systemic inflammation--the bells ring for complement and Toll in cooperation.
Source:
Elsevier BV
The structural basis of antibody-antigen recognition.
Source:
Frontiers Media SA
An international serum standard for application in assays to detect human complement activation products
Source:
Elsevier BV
Complement: a key system for immune surveillance and homeostasis
Source:
Springer Science and Business Media LLC
FDA Report: Eculizumab (Soliris®) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
Source:
Alphamed Press
Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
Source:
Frontiers Media SA
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Source:
HAL CCSD
Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.
Source:
Rockefeller University Press
TLR3 immune modulation and the role of CD14
Source:
Wiley
Complement in clinical medicine: Clinical trials, case reports and therapy monitoring
Source:
Elsevier
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Source:
Springer Science and Business Media LLC
Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc‐Fusion Proteins
Source:
Elsevier BV
Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
Source:
Elsevier BV
The role of the VL- and VH-segments in the preferential reassociation of immunoglobulin subunits.
Source:
Elsevier BV
IgG Fc engineering to modulate antibody effector functions
Source:
SpringerOpen
Linking provided by
